Modification(s)
None
Gene ID number
7040
Swiss Prot
P01137
French translation
anticorps
Immunogen range
280-330/390
Concentration
1ug per 1ul
Conjugation
Unconjugated
Target Antigen
TGF Beta 1+2+3
Cross reactivity
Human, Mouse, Rat
Category
Primary Antibodies
Also known as
TGF Beta 1+2+3 PAb
Clonality
Polyclonal antibody
Modification site(s)
Unmodified antibody
Clone number
Polyclonal antibody
Tested Applications
WB, IHC-P, IF(IHC-P)
Subcellular location
Extracellular, Secreted
Purification method
This antibody was purified via Protein A.
Long name
TGF Beta 1+2+3 Primary Polyclonal Antibody
Recommended dilutions
WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)
Synonym names
CED; LAP; DPD1; TGFB; TGFbeta; Transforming growth factor beta-1; TGF-beta-1; TGFB1
Cross reactive species details
Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.
Source
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human TGF Beta 1
Storage conditions
Keep the antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for up to 1 year.
Properties
If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.
Specificity
This is a highly specific antibody against TGF Beta 1+2+3. This antibody will preferentially react with TGFB1, but will also detect TGFB2 (93%) and TGFB3 (86%) based upon sequence similarity.
Background of the target antigen
Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development. At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells.